Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
INTERVENTIONAL
2008-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
prednisone
vinblastine
doxorubicin
gemcitabine
2
prednisone
vinblastine
doxorubicin
gemcitabine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
prednisone
vinblastine
doxorubicin
gemcitabine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Stage
* Clinical Stage IA, IB, IIA with at least one of the risk factors a-d given below
* Clinical Stage IIB with one or both risk factors c-d given below risk factors:
* Large mediastinal mass (≥ 1/3 of the greatest thorax diameter as measured by chest x-ray)
* Extranodal involvement
* High erythrocyte sedimentation rate (≥ 50 mm/h in patients without B-symptoms, ≥ 30 mm/h in patients with B-symptoms)
* Three or more involved lymph node areas
3. No prior therapy for Hodgkin's lymphoma (exception: pre-phase treatment with corticosteroids and vinca-alkaloids for a maximum of seven days may not preclude trial participation if clinically indicated and all staging examinations have been performed; all forms of prior radiotherapy preclude trial participation)
4. Age: 18-60 years
5. Signed informed consent with understanding of the study procedures and the investigational nature of the study
6. Patient agrees that personal data and tissue samples are provided to the GHSG (protection of privacy as defined by law will be ensured)
7. Life expectancy \> 3 months according to investigator judgement.
Exclusion Criteria
2. Prior or concurrent disease which prevents treatment according to protocol In particular the following contraindications:
* Chronic obstructive pulmonary disease with global insufficiency
* Symptomatic coronary heart disease
* Cardiomyopathy or cardiac insufficiency (NYHA value of EF \< 50% or FS \< 25%)
* Serious uncontrolled hypertension
* Uncontrollable infection
* Leucocyte concentration \< 3.000/mm3 or thrombocyte concentration \< 100.000/mm3
* Creatinin clearance \< 60 ml/min
* Bilirubin \> 2 mg/dl or GPT \> 100 U/l or GOT \> 100 U/I (exception: elevated values of Hodgkin's disease liver involvement)
* HIV-Infection according to HIV test
* Chronic or acute Hepatitis
3. HD as composite lymphoma
4. Prior chemotherapy or radiation
5. Malignant disease within the last 5 years (exceptions: basalioma, carcinoma in situ of the cervix uteri, completely resected melanoma TNMpT1)
6. Pregnancy, lactation, positive pregnancy test
7. Refusal to use effective contraception
8. WHO performance index \> 2
9. Long-term ingestion of corticosteroids (e.g. for chronic polyarthritis) or antineoplastic drugs (e.g. methotrexate)
10. Patient's lack of accountability, inability to appreciate the nature, meaning and consequences of the trial and to formulate his/her own wishes correspondingly
11. Non compliance: Refusal of blood products during treatment, epilepsy, drug dependency, change of residence abroad, prior cerebral injury or similar circumstances which appear to make protocol treatment or long-term follow-up impossible
12. Antiepileptic treatment
13. General intolerance of any protocol medication
14. Any contraindication for study medication according to the summaries of product information
15. Simultaneous participation in another clinical
16. Institutionalization by law
17. Relation of dependence with the sponsor's representative / trialist
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Cologne
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof. Dr. Andreas Engert
Prof.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andreas Engert, Prof
Role: PRINCIPAL_INVESTIGATOR
University of Cologne
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Cologne
Cologne, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PVAG-14 pilot
Identifier Type: -
Identifier Source: org_study_id